Find Therapeutics

Find Therapeutics Doses First Subject in Phase I Trial of FTX-101 for Chronic Optic Neuropathy

- Find Therapeutics initiated a Phase I clinical trial of FTX-101, a potential treatment for chronic optic neuropathy, after receiving FDA approval. - The Phase I trial is a two-part study evaluating the safety, tolerability, and pharmacokinetics of FTX-101 versus placebo in healthy volunteers. - FTX-101 is designed as a remyelinating agent that could restore vision by addressing demyelination in the visual pathways. - The company anticipates releasing data from the Phase I trial in the first half of next year, marking a significant step in developing a novel therapy.